Holen Sie sich die Stockscreener-App
99.62
4.64%
4.42
Handel nachbörslich:
99.62
Schlusskurs vom Vortag:
$95.20
Offen:
$94.94
24-Stunden-Volumen:
1.29M
Relative Volume:
1.19
Marktkapitalisierung:
$5.72B
Einnahmen:
$360.35M
Nettoeinkommen (Verlust:
$-149.57M
KGV:
-33.66
EPS:
-2.96
Netto-Cashflow:
$-81.27M
1W Leistung:
+10.65%
1M Leistung:
+31.29%
6M Leistung:
+5.06%
1J Leistung:
-29.26%
1-Tages-Spanne:
$93.78
$99.73
1-Wochen-Bereich:
$87.32
$99.73
52-Wochen-Spanne:
$73.16
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Firmenname
Glaukos Corporation
Sektor
Branche
Telefon
949-367-9600
Adresse
1 GLAUKOS WAY, ALISO VIEJO, CA
Vergleichen Sie GKOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
99.62 | 5.47B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
128.11 | 215.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.88 | 143.20B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
368.27 | 137.86B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.20 | 127.43B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 48.80B | 5.88B | 1.34B | 799.60M | 2.3489 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Buy |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Eingeleitet | Truist | Buy |
| 2023-11-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-14 | Fortgesetzt | Stephens | Overweight |
| 2022-10-04 | Eingeleitet | Needham | Buy |
| 2022-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2022-02-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2021-11-03 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-12-09 | Eingeleitet | Oppenheimer | Perform |
| 2020-11-17 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Eingeleitet | Jefferies | Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Sell |
| 2020-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Hochstufung | Berenberg | Hold → Buy |
| 2019-12-12 | Herabstufung | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Eingeleitet | BTIG Research | Neutral |
| 2018-08-30 | Eingeleitet | Berenberg | Hold |
| 2018-08-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Bestätigt | Stifel | Hold |
| 2018-06-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-03-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2016-10-27 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Glaukos Corporation Aktie (GKOS) Neueste Nachrichten
Glaukos President & COO Joseph Gilliam Sells 39% Of Holding - simplywall.st
Glaukos outlines $600M–$620M 2026 revenue outlook as Epioxa launch and iDose TR drive growth - MSN
Is Glaukos Corporation stock a safe buy before earningsTrade Risk Assessment & Low Drawdown Investment Ideas - newser.com
Investors Appear Satisfied With Glaukos Corporation's (NYSE:GKOS) Prospects As Shares Rocket 25% - simplywall.st
Will Glaukos Corporation stock benefit from infrastructure spendingWeekly Trading Summary & Daily Profit Focused Stock Screening - newser.com
Why analysts maintain buy rating on Glaukos Corporation stockJuly 2025 Retail & Verified Momentum Watchlists - newser.com
Glaukos gains as Goldman Sachs initiates at Buy on valuation - MSN
Glaukos Insider Sold Shares Worth $1,740,600, According to a Recent SEC Filing - MarketScreener
Gilliam, Glaukos Corp president, sells $1.74m in GKOS stock By Investing.com - Investing.com Nigeria
Gilliam, Glaukos Corp president, sells $1.74m in GKOS stock - Investing.com India
Why Glaukos Corporation stock stays undervaluedStop Loss & Capital Protection Trade Alerts - newser.com
How Glaukos Corporation stock moves in volatile trading sessions2025 Growth vs Value & Daily Volume Surge Trade Alerts - newser.com
How Glaukos Corporation stock performs in easing cycles2025 Winners & Losers & Weekly Consistent Profit Watchlists - newser.com
Will Glaukos Corporation stock keep raising dividendsBuy Signal & Consistent Return Investment Signals - newser.com
Is Glaukos Corporation stock undervalued vs historical averagesMarket Movement Recap & AI Forecasted Entry and Exit Points - newser.com
Risk vs reward if holding onto Glaukos CorporationQuarterly Performance Summary & Scalable Portfolio Growth Ideas - newser.com
Backtesting results for Glaukos Corporation trading strategiesQuarterly Investment Review & Capital Efficient Trade Techniques - newser.com
Is Glaukos Corporation stock overvalued by current metricsJuly 2025 Action & Community Consensus Picks - newser.com
Glaukos Corporation (GKOS) Advances Next-Gen Glaucoma and Corneal Therapies, Eyes FDA Approval for Epioxa - MSN
Key metrics from Glaukos Corporation’s quarterly dataWeekly Risk Summary & AI Optimized Trading Strategy Guides - newser.com
Will Glaukos Corporation continue its uptrendJuly 2025 EndofMonth & Risk Controlled Daily Trade Plans - newser.com
Why Glaukos Corporation stock appears on watchlistsJuly 2025 Decliners & Community Trade Idea Sharing Platform - newser.com
How higher bond yields impact Glaukos Corporation stockPortfolio Value Report & Real-Time Volume Analysis Alerts - newser.com
Combining machine learning predictions for Glaukos CorporationPortfolio Profit Report & Breakout Confirmation Alerts - newser.com
Finanzdaten der Glaukos Corporation-Aktie (GKOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):